ASCO 2015 Highlights

The Use of Chemotherapy in the Metastatic Setting
The Use of Chemotherapy in the Metastatic Setting
By Dr Matthew Goetz
Breast Cancer, SABCS Highlights
Videos
Dr Matthew Goetz believes that, as more mature data come into existence, the demonstration of a survival advantage will guide more patients with metastatic breast cancer to try CDK4/6 inhibitors plus aromatase inhibitors instead of chemotherapy.
Read Article
The Mechanism of Action of CDK4/6 Inhibitors
The Mechanism of Action of CDK4/6 Inhibitors
By Dr Matthew Goetz
Breast Cancer, SABCS Highlights
Videos
Dr Matthew Goetz explains the rationale for using CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer.
Read Article
HER2-Positive Breast Cancer and CDK4/6 Inhibitors
HER2-Positive Breast Cancer and CDK4/6 Inhibitors
By Dr Hope Rugo
Breast Cancer, SABCS Highlights
Videos
Dr Hope Rugo discusses studies that are aiming to evaluate the effect that CDK4/6 inhibitors have on patients with HER2-positive breast cancer.
Read Article
Disease Progression with a CDK4/6 Inhibitor plus an Aromatase Inhibitor
Disease Progression with a CDK4/6 Inhibitor plus an Aromatase Inhibitor
By Dr Hope Rugo
Breast Cancer, SABCS Highlights
Videos
Hope S. Rugo, MD, describes how she would treat a patient with HER-positive metastatic breast cancer that has progressed with a CDK4/CDK6 inhibitor plus an aromatase inhibitor.
Read Article
What Differentiates Abemaciclib, Ribociclib, and Palbociclib?
What Differentiates Abemaciclib, Ribociclib, and Palbociclib?
By Dr Hope Rugo
Breast Cancer, SABCS Highlights
Videos
Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer.
Read Article
CDK4/6 Inhibitors vs Chemotherapy for Patients with Metastatic Breast Cancer
CDK4/6 Inhibitors vs Chemotherapy for Patients with Metastatic Breast Cancer
By Dr Hope Rugo
Breast Cancer, SABCS Highlights
Videos
Read Article
Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer
Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer
By Dr Hope Rugo
Breast Cancer, SABCS Highlights
Videos
Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy.
Read Article
Hot Topics at SABCS 2017
Hot Topics at SABCS 2017
By Dr Hope Rugo
Breast Cancer, SABCS Highlights
Videos
Dr Hope Rugo provides an overview of some hot topics being covered at SABCS 2017 in the areas of hormone therapy, immunotherapy, neoadjuvant therapy, and more.
Read Article
 Online First
Opdivo First Immunotherapy Approved for Hepatocellular Carcinoma
FDA Approvals, News & Updates
December 2017, Vol 8, No 5
On September 22, 2017, the FDA granted accelerated approval to nivolumab (Opdivo; Bristol-Myers Squibb) for the treatment of hepatocellular carcinoma (HCC)—the most common type of liver cancer—in patients who previously received sorafenib treatment. Opdivo received priority review for this indication.
Read Article
Identifying Long-Term Unmet Needs in Survivorship Care
By Meg Barbor, MPH
Survivorship, Policies & Guidelines
December 2017, Vol 8, No 5
New Orleans, LA—The number of cancer survivors is increasing. To keep up with this trend, survivorship care must evolve and become more efficient, insists Jennifer R. Klemp, PhD, MPH, MA, Director, Cancer Survivorship, University of Kansas Cancer Center, Westwood. A growing number of patients are living with or through their disease, while the provider workforce is shrinking.
Read Article

Page 122 of 330

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.